Welcome to our dedicated page for Avantor news (Ticker: AVTR), a resource for investors and traders seeking the latest updates and insights on Avantor stock.
Avantor, Inc. (NYSE: AVTR) is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. This news page aggregates company announcements, earnings updates and other disclosures so readers can follow how Avantor’s operations, portfolio and governance evolve over time.
Recent news releases describe Avantor’s participation in investor conferences, quarterly earnings reports, leadership and board appointments, and product and service developments. Examples include announcements about the timing of quarterly and full-year earnings releases and related conference calls, as well as participation in events such as the J.P. Morgan Healthcare Conference. These items provide context on how the company communicates with the investment community and presents its financial performance.
Product- and operations-focused news highlights areas such as bioprocessing, biomanufacturing and laboratory services. Avantor has reported the launch of a sterile sampling platform and PUPSIT assemblies for bioprocessing, the development of a biodegradable viral inactivation detergent recognized with an Edison Patent Award, and the expansion of its Centralized Service Center model with a facility serving the Greater Boston area. These updates illustrate how the company positions its tools and services within scientific and industrial workflows.
Corporate governance news includes the appointment of new directors and senior executives, such as additions to the Board of Directors and the creation of an Executive Vice President and Chief Operating Officer role. Together, these news items offer insight into Avantor’s strategic priorities, leadership changes and ongoing initiatives. Investors, analysts and industry participants can use this page to monitor company communications and official announcements over time.
Avantor (NYSE: AVTR) has announced a global initiative to support communities amid the COVID-19 pandemic. The company is donating over 1.5 million surgical masks and thermometers to schools in Mumbai and Delhi. Additionally, Avantor Foundation has granted nearly $350,000 to various organizations focusing on healthcare and STEM education. These efforts align with Avantor's mission to promote science for goodness and enhance patient outcomes through educational support and healthcare improvements.
Avantor, a leading provider of mission-critical products and services, will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021. CEO Michael Stubblefield will represent the company in a segment starting at approximately 9:10 a.m. Eastern Time. Investors can access a live webcast on Avantor's investor relations website, which will be available for replay until January 31, 2021.
With a global reach, Avantor serves over 225,000 customer locations in more than 180 countries, supporting critical research and development activities.
Avantor (NYSE: AVTR) will participate in the Evercore ISI 3rd Annual HealthCONx Virtual Conference on December 2, 2020. The event will feature a segment with Michael Stubblefield, President and CEO, starting at approximately 2:40 p.m. ET. Investors can access the live webcast via Avantor's investor relations website, and it will be available for replay until December 31, 2020. Avantor is a global leader in providing mission-critical products and services to various industries, supporting over 225,000 customer locations worldwide.
Avantor, Inc. (NYSE: AVTR) has launched a new biorepository and sample archiving facility in Frankfurt, Germany, enhancing access to samples within 24 hours for researchers. This facility is crucial for the growing demand for clinical trials, especially during the COVID-19 pandemic. Avantor boasts a 40-year heritage in biorepository services, having stored over 100 million research assets without failure. The facility has earned DGNB 'Gold' certification for sustainable construction, underscoring Avantor's commitment to ecological and economic responsibility.
Avantor, a leading global provider of mission-critical products, will participate in the Jefferies Virtual London Healthcare Conference on November 18, 2020. Michael Stubblefield, President and CEO of Avantor, is scheduled to speak at approximately 11:25 a.m. Eastern Time. Investors and attendees can access a live webcast through Avantor's investor relations website, with a replay available until November 30, 2020. Avantor serves over 225,000 customer locations globally, supporting vital research across various industries.
Avantor (NYSE: AVTR) has partnered with G-CON Manufacturing to provide mobile lab units, known as LabPODs, aimed at expediting diagnostic testing, particularly for COVID-19. These mobile labs will allow for quicker on-site testing, reducing wait times for results and potentially slowing infection rates. Avantor will supply the necessary equipment and expertise for these labs, enhancing diagnostic capabilities not only for COVID-19 but also for other microbial and analytical evaluations. This collaboration represents a significant step in transforming the accessibility of critical testing services.
Avantor, a global provider of mission-critical products and services, announced the pricing of a secondary offering of 71,569,765 shares of its common stock at $25.25 per share. This offering, conducted by certain stockholders including New Mountain Capital, reflects an increase from the initially proposed 71,339,001 shares. The underwriters have a 30-day option to purchase up to an additional 7,156,975 shares. The offering is expected to close on November 10, 2020.
Avantor, Inc. (NYSE: AVTR) announced an underwritten secondary offering of 71,339,001 shares of common stock by certain stockholders, including an affiliate of New Mountain Capital, LLC. The underwriters, Goldman Sachs & Co. LLC and J.P. Morgan, may also purchase an additional 7,133,898 shares within 30 days. Avantor will not receive any proceeds from this offering, which has been registered with the SEC.
Prospective investors can obtain the necessary prospectus from the underwriters. This press release does not constitute an offer or solicitation for the shares.
Avantor executives participated in the Cell & Gene Therapy Bioprocessing & Commercialization Conference, discussing essential topics like process efficiency and scalability within the biopharmaceutical sector.
Dr. Ger Brophy highlighted the need for operational efficiency and automation to enhance accessibility to cell and gene therapies. Claudia Berrón emphasized collaboration among industry leaders to navigate challenges posed by COVID-19, focusing on supply chain disruptions and clinical trial delays. Avantor aims to support the development of novel treatments by partnering with leading pharmaceutical companies.
Avantor announced the pricing of €650 million of 2.625% Senior First Lien Notes due November 2025, up from a previously announced €550 million. The offering closes on November 6, 2020. The Notes are guaranteed by Vail Holdco Sub LLC and its subsidiaries, secured by tangible and intangible assets. Proceeds will redeem existing 6.000% and 4.750% Senior First Lien Notes due 2024. The offering is made under exemptions of the Securities Act, available only to qualified institutional buyers.